Skip to main content

Table 3 Mixed Model Analysis by Treatment, Age, and Treatment by Age for Predose and Postdose Time Points*

From: Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day

Time Point (hr)

Mixed Model Statistical Analysis

SKAMP-D

SKAMP-A

SKAMP-Total

SKAMP-QoL

PERMP-A

PERMP-C

  

F Value

P Value

F Value

P Value

F Value

P Value

F Value

P Value

F Value

P Value

F Value

P Value

-0.5

Treatment

3.69

.0574

10.88

.0013

48.67

<.0001

133.44

<.0001

34.98

<.0001

37.63

<.0001

 

Age

8.65

.0040

3.55

.0623

5.76

.0181

0.95

.3307

1.49

.2251

1.60

.2080

 

Treatment by age

0.10

.7574

0.72

.3971

0.31

.5771

0.02

.9027

0.20

.6580

0.17

.6793

1.5

Treatment

27.82

<.0001

19.41

<.0001

42.98

<.0001

2.92

.0903

18.95

<.0001

30.00

<.0001

 

Age

6.83

.0102

6.63

.0113

6.93

.0097

0.03

.8716

0.59

.4430

0.54

.4627

 

Treatment by age

2.38

.1255

1.91

.1693

2.32

.1307

0.09

.7625

0.49

.4876

0.02

.8854

2.5

Treatment

121.66

<.0001

79.31

<.0001

204.35

<.0001

61.19

<.0001

94.10

<.0001

103.60

<.0001

 

Age

7.25

.0082

3.70

.0571

7.99

.0056

2.49

.1172

0.14

.7066

0.23

.6303

 

Treatment by age

5.99

.0159

0.01

.9253

1.93

.1672

0.02

.8971

1.74

.1902

1.27

.2619

5.0

Treatment

126.22

<.0001

79.64

<.0001

213.18

<.0001

89.58

<.0001

117.59

<.0001

122.97

<.0001

 

Age

5.20

.0245

6.59

.0116

8.64

.0040

2.49

.1173

0.04

.8480

0.07

.7974

 

Treatment by age

5.57

.0201

0.49

.4865

4.54

.0353

2.72

.1018

4.41

.0379

4.25

.0415

7.5

Treatment

109.78

<.0001

98.23

<.0001

215.28

<.0001

76.54

<.0001

134.00

<.0001

137.53

<.0001

 

Age

5.27

.0236

6.93

.0097

7.27

.0081

0.00

.9885

0.21

.6473

0.35

.5544

 

Treatment by age

0.12

.7342

6.55

.0118

2.06

.1543

0.06

.8090

1.55

.2159

1.38

.2418

10

Treatment

72.09

<.0001

68.52

<.0001

150.65

<.0001

32.26

<.0001

108.63

<.0001

115.45

<.0001

 

Age

3.26

.0736

11.15

.0011

7.22

.0083

0.23

.6300

0.60

.4393

0.64

.4271

 

Treatment by age

0.83

.3636

0.04

.8433

0.05

.8172

1.00

.3186

0.20

.6556

0.05

.8202

12

Treatment

34.82

<.0001

44.84

<.0001

100.99

<.0001

30.71

<.0001

74.62

<.0001

81.57

<.0001

 

Age

5.34

.0227

9.44

.0027

12.67

.0006

3.97

.0487

0.13

.7163

0.06

.8065

 

Treatment by age

0.42

.5170

0.06

.8007

0.00

.9549

1.06

.3058

0.27

.6020

0.13

.7158

13

Treatment

8.29

.0048

34.69

<.0001

38.63

<.0001

10.26

.0018

67.42

<.0001

68.29

<.0001

 

Age

5.56

.0201

7.40

.0076

9.48

.0026

0.34

.5637

0.03

.8639

0.09

.7587

 

Treatment by age

0.01

.9293

0.45

.5018

0.45

.5051

2.15

.1458

0.02

.8820

0.02

.8913

  1. LDX: lisdexamfetamine dimesylate; PERMP: Permanent Product Measure of Performance; PERMP-A: PERMP-Attempted; PERMP-C: PERMP-Correct; SKAMP: Swanson, Kotkin, Agler, M-Flynn, and Pelham; SKAMP-A: SKAMP-Attention; SKAMP-D: SKAMP-Deportment.
  2. *Degrees of freedom (df) = 110 for all analyses except the 7.5-hour postdose time point where df = 109 for all analyses.
Back to article page

Child and Adolescent Psychiatry and Mental Health

ISSN: 1753-2000